|
|
Juvenile Arthritis - A Niche In The MarketPublished by: Datamonitor Published: Dec. 21, 2005 - 46 Pages Table of ContentsTABLE OF CONTENTS CHAPTER 1 EXECUTIVE SUMMARY 4 Introduction 4 Scope and coverage of the Brief 4 Key findings about the topic 5 CHAPTER 2 DISEASE CLASSIFICATION AND EPIDEMIOLOGY 9 Classification of juvenile arthritis 9 Epidemiology 14 CHAPTER 3 CURRENT TREATMENTS FOR JIA 18 The changing treatment algorithm 18 Clinical trial outcome measures 21 Therapies 23 CHAPTER 4 PIPELINE INNOVATIONS AND CLINICAL TRIALS 31 Commercial attractiveness of the market 31 Pipeline trial results 34 APPENDIX 42 Bibliography 42 Disclaimer 46 AbstractIntroductionJuvenile arthritis is the next indication due for approval for blockbuster biologic therapies Remicade (infliximab) and Humira (adalimumab). Pediatric rheumatology is a growing specialty that offers high unmet need in terms of effective well-tested treatments. Rheumatic diseases remain a significant cause of chronic illness in children, with juvenile arthritis one of the most prevalent types. Scope Outline of the various juvenile arthritis classifications and guidelines Insight into the use of key drug classes including disease modifying and pain killing treatments Assess the future product positioning and life-cycle management strategies as commercially viable strategies are proposed for drug development in JIA Read the latest data for novel products in clinical trials for this indication Highlights Classifications for juvenile arthritis are often dissimilar, and vary from the US to the EU. The International League for Arthritis Research (ILAR) has outlined a definitive Juvenile Idiopathic Arthritis (JIA) definition which is now being adopted in clinical trials. Pathology differs from adult RA mechanisms, but IL-1 and IL-6 appear to be key mediators and inhibition of each has shown promise in JIA. Kineret (anakinra) the only IL-1 inhibitor currently available, does not appear to be in development for JIA, but Actemra (tocilizumab) is expected to launch in both adult and juvenile RA in the near future. Orphan designation qualifies the sponsor of the product for tax credit and marketing incentives, and all three biologic TNF-inhibitors currently have orphan designation in the US but only Enbrel (etanercept) is approved in this indication. Novel products are advised to apply for this designation. Reasons to Purchase Identify the key definitions and subtypes involved in juvenile arthritis and evaluate the latest guidelines and treatment algorithms Develop commercial strategies for juvenile arthritis approval Understand the latest trial data from novel biologic therapies such as IL-6 inhibitor tocilizumab and IL-1 inhibitor anakinra Get Full Details About This Report >> |
|
|||
|
About MarketResearch.com
|
||||